Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.150
-0.130 (-3.04%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Arbutus Biopharma Employees
Arbutus Biopharma had 19 employees as of December 31, 2025. The number of employees decreased by 25 or -56.82% compared to the previous year.
Employees
19
Change (1Y)
-25
Growth (1Y)
-56.82%
Revenue / Employee
$741,211
Profits / Employee
-$1,763,211
Market Cap
817.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| MeiraGTx Holdings | 403 |
| Kura Oncology | 260 |
| ARS Pharmaceuticals | 163 |
| Allogene Therapeutics | 152 |
| Cullinan Therapeutics | 109 |
| Theravance Biopharma | 90 |
| Alto Neuroscience | 68 |
ABUS News
- 13 days ago - Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - GlobeNewsWire
- 5 weeks ago - Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant - WSJ
- 2 months ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 2 months ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 2 months ago - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 2 months ago - Moderna Resolves Global Patent Litigation with Arbutus/Genevant - Accesswire
- 5 months ago - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire